|Incremental cost-effectiveness ratio (ICER) for sensitivity analyses|
|Parameter||Routine vaccination||Routine and a catch-up vaccination|
|US$ per QALYs||US$ per QALYs|
|Cost per year of life saved (no quality of life adjustments)||253||503|
|HPV16/18-related cervical diseases only||448||698|
|Duration of vaccine protection = 20 years||Dominated1||656|
|Vaccine coverage= 50% for routine and 60% for catch-up||106||250|
|Vaccine coverage= 95% for routine and 98% for catch-up||258||425|
|High cost of vaccine series (increased by 25%)||406||686|
|High cost of treating HPV-related disease (increased by 25%)||86||326|
|Low cost of treating HPV-related disease (decreased by 25%)||350||573|
|Discounted at 0%||Cost saving||Cost saving|
|Discounted at 5%||900||1201|
1 A strategy is “weakly” dominated if a more effective strategy has a lower incremental cost-effectiveness ratio.
2 Pessimistic scenario assumes low HPV-related disease cost (decreased by 25%), 20 years of vaccine protection, and high health utilities (0.97 for HPV-related disease).
Kawai et al.
Kawai et al. BMC Infectious Diseases 2012 12:250 doi:10.1186/1471-2334-12-250